Solara Active Pharma Sciences Allots 1,500 Equity Shares Under ESOP 2018

2 min read     Updated on 17 Dec 2025, 12:00 PM
scanx
Reviewed by
Naman SScanX News Team
Overview

Solara Active Pharma Sciences Limited allotted 1,500 equity shares under its Employee Stock Option Plan 2018 on December 17, 2025, at an exercise price of ₹375 per share. The allotment generated ₹5.63 lakhs and increased the company's total issued share capital to 4,81,71,562 shares worth ₹48.17 crores. The newly issued shares carry identical rights to existing equity shares and comply with all SEBI regulatory requirements.

27498651

*this image is generated using AI for illustrative purposes only.

Solara Active Pharma Sciences Limited has announced the allotment of 1,500 equity shares under its Employee Stock Option Plan 2018, as approved by the Board of Directors on December 17, 2025. The allotment was made pursuant to the exercise of vested options under the company's employee stock option scheme.

Share Allotment Details

The Board of Directors approved the allotment of 1,500 equity shares with a face value of ₹10 each, fully paid up, against the exercise of vested options. The shares were allotted at an exercise price of ₹375 per share, generating total proceeds of ₹5.63 lakhs for the company.

Parameter Details
Number of Shares Allotted 1,500 equity shares
Face Value per Share ₹10.00
Exercise Price per Share ₹375.00
Total Money Realized ₹5.63 lakhs
Date of Issue July 22, 2024
ISIN Number INE624Z01016

Impact on Share Capital Structure

Following the ESOP allotment, the company's paid-up share capital structure has been updated. The total number of issued shares increased from 4,81,70,062 to 4,81,71,562 equity shares.

Share Capital Before Allotment:

Category Number of Shares Paid-up Amount (₹)
Equity Shares - Fully Paid 3,61,71,307 36,17,13,070.00
Equity Shares - Partly Paid 1,17,61,546 8,23,30,822.00
Equity Shares - Partly Paid 2,37,209 8,30,231.50
Total Paid-up Capital 4,81,70,062 44,48,74,123.50

Share Capital After Allotment:

Category Number of Shares Paid-up Amount (₹)
Equity Shares - Fully Paid 3,61,72,807 36,17,28,070.00
Equity Shares - Partly Paid 1,17,61,546 8,23,30,822.00
Equity Shares - Partly Paid 2,37,209 8,30,231.50
Total Paid-up Capital 4,81,71,562 44,48,89,123.50

Regulatory Compliance and Rights

The allotment was made in compliance with SEBI regulations, including Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Regulation 10(c) of SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

The newly allotted equity shares rank pari-passu with existing equity shares of the company in all respects, carrying identical voting rights and dividend entitlements. The company reported diluted earnings per share of ₹0.19 per share pursuant to this equity share issuance.

Exercise Terms and Conditions

Under the Solara Employee Stock Option Plan 2018, options must be exercised within 120 days from the date of vesting. The exercise period provides employees with a defined timeframe to convert their vested options into equity shares. The options cannot be exercised after the expiry of the 120-day exercise period.

The company is listed on both the National Stock Exchange of India Limited and BSE Limited, with trading symbols SOLARA and SOLARAPP1 respectively. The original ESOP scheme filing was completed on October 24, 2018, with both exchanges.

Solara Active Pharma Reports 39% EBITDA Decline in Q2 FY26 Due to Mangalore Facility Shutdown

2 min read     Updated on 11 Nov 2025, 06:41 PM
scanx
Reviewed by
Jubin VScanX News Team
Overview

Solara Active Pharma Sciences faced challenges in Q2 FY26 due to an unscheduled shutdown at its Mangalore facility. Revenue decreased by 2% to ₹314.00 crores, while EBITDA fell 39% to ₹35.00 crores. Gross margin declined to 51.00%. The shutdown resulted in lost sales of ₹30.00-35.00 crores and a gross margin impact of ₹18.00-20.00 crores. Despite setbacks, the company cleared a U.S. FDA audit at the Mangalore facility. Management maintains a positive outlook, expecting 10% revenue growth and 15-20% EBITDA growth for FY26. The company plans to reduce debt to ₹446.00 crores by Q1 FY27.

24412296

*this image is generated using AI for illustrative purposes only.

Solara Active Pharma Sciences - PP , a leading pharmaceutical company, reported a challenging second quarter for FY2026, with a significant decline in EBITDA due to an unscheduled operational shutdown at its Mangalore facility.

Financial Performance

Metric Q2 FY26 Q-o-Q Change
Revenue ₹314.00 crores -2%
EBITDA ₹35.00 crores -39%
Gross Margin 51.00% -264 bps
Operating Costs ₹120.00 crores +₹9.00 crores

The company's revenue saw a marginal decline of 2% quarter-on-quarter, while EBITDA dropped significantly by 39% to ₹35.00 crores. The gross margin, although healthy at 51.00%, decreased by 264 basis points compared to the previous quarter.

Mangalore Facility Shutdown Impact

The unscheduled operational shutdown at the Mangalore facility, which lasted for 3-4 weeks in August, was the primary reason for the quarter's underperformance. This shutdown resulted in:

  • Lost sales of approximately ₹30.00-35.00 crores
  • Gross margin impact of ₹18.00-20.00 crores
  • One-time upgrade costs of ₹4.00 crores

Despite these challenges, Solara Active Pharma Sciences successfully cleared a U.S. FDA audit at the Mangalore facility with only two minor observations of a procedural nature.

Business Highlights

  • Regulated markets contributed 75% of overall sales
  • Debt reduced by ₹153.00 crores during H1 FY26, a 20% reduction from the opening debt
  • The company maintains a portfolio of 90-95 DMF filings in the U.S., with 35-40 active products

Future Outlook

Management remains optimistic about the company's prospects:

  • Expects the disruption to be temporary
  • Maintains outlook of 10% revenue growth and 15-20% EBITDA growth for FY26
  • Plans to further reduce debt to ₹446.00 crores by Q1 FY27
  • Focuses on improving profitability through cost improvement programs and operating cost optimization

Management Commentary

Sandeep Rao, Managing Director and CEO, stated, "While these factors did impact us in Q2, they are transitory. The underlying fundamentals of the business remain strong, supported by a resilient operating model, a robust compliance framework, and a diversified portfolio across all our key markets."

Sarat Kumar, CFO, added, "We are confident that both the medium-term as well as long-term business fundamentals remain the same, and we look forward to a quick improvement in our financial performance in the upcoming quarters."

Solara Active Pharma Sciences continues to focus on its transformation journey, aiming to pivot from reset to sustainable, scalable, and reliable growth. The company's management remains committed to improving operational efficiencies and maintaining a healthy gross margin profile in the coming quarters.

More News on Solara Active Pharma Sciences - PP
Explore Other Articles